Introduction {#s1}
============

Tendons are composed primarily of a dense, highly aligned collagen extracellular matrix (ECM), and connect muscle to bone to transmit mechanical forces throughout the body. Following injury, tendon demonstrates limited regenerative potential and heals through a scar-mediated fibrotic process involving abundant, disorganized ECM deposition. While scar tissue can impart some mechanical strength to the healing tissue, it is also mechanically inferior to native tendon and dramatically impairs normal tendon function resulting in substantial morbidity. In addition, scar tissue increases tendon bulk and forms adhesions to the surrounding tissues, impeding normal range of motion (ROM). This pathological response to injury represents a major clinical burden considering there are over 300,000 surgical tendon repairs in the United States annually ([@bib38]), and a high proportion of primary tendon repairs heal with unsatisfactory outcomes and impaired function ([@bib4]; [@bib17]). Despite this burden, there is currently no consensus biological or pharmacological approach to improve tendon healing, due in large part to a paucity of information on the cellular and molecular components involved.

S100a4 (also known as *Fsp1*, *Mts1*, *Pk9a*) is a member of the S100 family of EF-hand Ca^2+^-binding proteins, and is a potent regulator of fibrosis in many tissues including the liver ([@bib9]; [@bib32]), lung ([@bib27]), heart ([@bib52]) and oral submucosa ([@bib60]). An increase in the proportion of S100a4^+^ cells is characteristic of many fibrotic conditions ([@bib15]; [@bib27]), and elevated serum S100a4 levels positively correlate with fibrosis clinically ([@bib9]). Moreover, the therapeutic potential of S100a4 inhibition is suggested by S100a4-cell depletion studies and S100a4 RNAi treatments in which fibrosis was halted, or effectively reversed ([@bib9]; [@bib23]; [@bib36]). While depletion of S100a4^+^ cells can inhibit fibrotic progression, S100a4 can also function as an intra- and extracellular signaling molecule to impact cellular processes including motility, survival, differentiation, and contractility ([@bib7]; [@bib42]). Additionally, the effects of S100a4 are cell and tissue-type dependent. We have previously shown that *S100a4*-Cre efficiently targets resident tendon cells ([@bib1]), however, the specific function of S100a4 and whether that function is primarily cell-autonomous or cell non-autonomous during scar-mediated fibrotic tendon healing is unknown.

In the present study we delineate the relative contributions of S100a4 expression and S100a4^+^ cells to scar-mediated tendon healing and investigated the effects of S100a4 haploinsufficiency on macrophage and tendon cell function, the cell non-autonomous extracellular signaling function of S100a4 during tendon healing, as well as the fate and function of S100a4-lineage cells in the healing tendon. We have identified S100a4 haploinsufficiency as a novel model of regenerative tendon healing and defined a requirement for S100a4^+^ cells in the restoration of mechanical properties during tendon healing. These data identify S100a4 signaling as a novel target to improve tendon healing and demonstrate the efficacy of pharmacological inhibition of S100a4 signaling to improve functional outcomes during healing.

Results {#s2}
=======

S100a4 is expressed by resident tendon cells and the S100a4^+^population expands during healing {#s2-1}
-----------------------------------------------------------------------------------------------

Spatial localization of S100a4 was examined before and after flexor digitorum longus (FDL) tendon repair surgery in S100a4-Cre; ROSA-Ai9 reporter mice to trace S100a4-lineage cells (S100a4^Lin+^; [Figure 1A & B](#fig1){ref-type="fig"}), and S100a4-GFP^promoter^ mice to identify cells actively expressing S100a4 (S100a4-GFP^promoter+^; [Figure 1D and E](#fig1){ref-type="fig"}). Most resident tendon cells were S100a4^Lin+^ in the uninjured tendon. Following tendon repair, S100a4^Lin+^ cells were located in the native tendon and bridging scar tissue at D7 and D14 post-surgery ([Figure 1B](#fig1){ref-type="fig"}). Quantitatively, there was a transient reduction in the S100a4^Lin+^ area at D7, relative to un-injured tendon. However, by 14 there was no significant difference ([Figure 1C](#fig1){ref-type="fig"}). Many resident tendon cells were actively expressing S100a4 at baseline, however many S100a4^-^ cells were also present ([Figure 1E](#fig1){ref-type="fig"}). Following injury, there were abundant S100a4-GFP^promoter+^ cells in the bridging scar tissue from D3 to D14, with S100a4-GFP^promoter+^ cells persisting at least through D28 ([Figure 1E](#fig1){ref-type="fig"}). Interestingly, the S100a4-GFP^promoter+^ area was significantly increased at D14 relative to D3, D7 and D28 (p=0.05) (Fig. F). Notably, the persistence of the S100a4-GFP^promoter+^ population was also observed in the healing Achilles tendon ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), suggesting potential conservation of S100a4 function between tendons. Consistent with changes in spatial expression over time, *S100a4* mRNA expression increased from D3 to a peak at D10, followed by a progressive decline through D28 ([Figure 1G](#fig1){ref-type="fig"}).

![S100a4 is expressed by resident tenocytes and the S100a4^+^cell population expands during tendon healing.\
(**A and B**) S100a4-Cre; Rosa-Ai9 reporter mice demonstrate efficient targeting of resident tendon cells. Following injury, the S100a4-lineage (S100a4^Lin+^) population expands, with S100a4^Lin+^ cells in the native tendon stubs and the bridging scar tissue at D7 and D14 post-surgery. Tendons are outlined in white, and bridging granulation tissue outlined in blue. (**C**) Quantification of S100a4^Lin+^ area over time. (\*) indicates p\<0.05 (1-way ANOVA). (**D**) The S100a4-GFP^promoter^ construct identifies cells actively expressing S100a4 (S100a4-GFP^promoter+^). (**E**) A subpopulation of resident tenocytes is S100a4-GFP^promoter+^ at baseline, and the S100a4-GFP^promoter+^ population increases following injury, with S100a4-GFP^promoter+^ cells observed in the bridging scar tissue and native tendon ends through D28 post-surgery. Tendons are outlined in white, and bridging granulation tissue outlined in orange, (\*) identifies sutures. (**F**) Quantification of the S100a4-GFP^promoter+^ area over time. (\*) indicates p\<0.05 (1-way ANOVA). (**G**) qPCR analysis of S100a4 during tendon healing demonstrates peak *S100a4* expression at D10, followed by a progressive decline through D28 (n = 3 per time-point). (\*) indicates p\<0.05 vs. D3 repair (1-way ANOVA). Data were normalized to expression in D3 repairs, and the internal control β-actin.](elife-45342-fig1){#fig1}

S100a4 haploinsufficiency promotes regenerative, mechanically superior tendon healing {#s2-2}
-------------------------------------------------------------------------------------

To determine the functional implications of decreasing *S100a4* expression during FDL tendon healing ([Figure 2A](#fig2){ref-type="fig"}), we utilized S100a4 haploinsufficient mice (S100a4^GFP/+^), which results in a 50% reduction in *S100a4* mRNA expression in the tendon ([Figure 2B](#fig2){ref-type="fig"}), as well as a robust decrease in S100a4 protein expression during tendon healing ([Figure 2C](#fig2){ref-type="fig"}). S100a4 haploinsufficiency did not alter baseline tendon function, with no significant differences observed in MTP Flexion Angle (p=0.22), Gliding Resistance (p=0.094), max load at failure (p=0.4), or stiffness (p=0.6) in un-injured contralateral control tendons ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In addition, decreased *S100a4* expression did not noticeably alter the spatial localization of S100a4^+^ cells in either the un-injured tendon or at D14 post-surgery ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). However, at D14 post-surgery, functional outcomes of scar formation in healing S100a4^GFP/+^ tendons were significantly improved compared to WT. A significant 36% increase in MTP Flexion Angle was observed in S100a4^GFP/+^ repairs, relative to WT (p=0.04) ([Figure 2D](#fig2){ref-type="fig"}). Gliding Resistance was significantly decreased by 43% in S100a4^GFP/+^ repairs, relative to WT (p=0.028) ([Figure 2E](#fig2){ref-type="fig"}), suggesting a reduction in scar formation in S100a4^GFP/+^ repairs. In addition, maximum load at failure was significantly increased (+35%) in S100a4^GFP/+^ repairs relative to WT (p=0.003) ([Figure 2F](#fig2){ref-type="fig"}), while stiffness was increased 28% in S100a4^GFP/+^ repairs, relative to WT, however this increase was not statistically significant (p=0.08) ([Figure 2G](#fig2){ref-type="fig"}). Taken together, these data suggest that S100a4 haploinsufficiency improves functional outcomes, while also improving tendon strength.

![S100a4 haploinsufficiency promotes regenerative, mechanically superior tendon healing.\
(**A**) S100a4^GFP/+^ haploinsufficient and wild type (WT) littermates underwent transection and repair of the FDL tendon, and tendons were harvested at D14 post-surgery. (**B**) *S100a4* mRNA expression was reduced by 50% in S100a4^GFP/+^ tendon repairs, relative to WT (n = 3 per group). (**C**) A substantial reduction in S100a4 protein expression was observed in S100a4^GFP/+^ tendon repairs, relative to WT. Tendon ends are outlined in blue and bridging scar tissue outlined in black (n = 3--4 per group). (**D--G**) At D14, MTP Flexion Angle was significantly increased in S100a4^GFP/+^ repairs (**D**), and Gliding Resistance was significantly decreased in S100a4^GFP/+^ repairs (**E**). Max load at failure was significantly improved in S100a4^GFP/+^ repairs (**F**), while no change in Stiffness was observed between genotypes (**G**) (n = 7--10 per group). (\*) indicates p\<0.05, (\*\*) indicates p\<0.01 between genotypes, n = 7--10 for (**D--G**) (un-paired t-test).](elife-45342-fig2){#fig2}

S100a4 haploinsufficiency improves tendon morphology and decreases myofibroblast content {#s2-3}
----------------------------------------------------------------------------------------

Morphologically, both Alcian blue Hematoxylin/Orange G (ABH/OG) and picrosirius red staining demonstrate collagen fibers bridging the tendon ends in both WT and S100a4 haploinsufficient mice at D14 (blue arrows, [Figure 3A](#fig3){ref-type="fig"}). Quantitatively, *Col1a1* expression was significantly increased 5.6-fold (p=0.0095) in S100a4^GFP/+^ repairs, relative to WT repairs ([Figure 3B](#fig3){ref-type="fig"}), while no change in *Col3a1* or *Scx* were observed between groups at D14 ([Figure 3C and D](#fig3){ref-type="fig"}). Expression of the myofibroblast marker *α-SMA* was decreased 2.4-fold in S100a4^GFP/+^ repairs, relative to WT (p=0.02) ([Figure 3E](#fig3){ref-type="fig"}). Consistent with this, a marked decrease in α-SMA staining was also observed in S100a4^GFP/+^ repairs, relative to WT (white arrows, [Figure 3F](#fig3){ref-type="fig"}). These data suggest that S100a4 haploinsufficiency promotes regenerative tendon healing via deposition of a Col1 ECM and a decrease in pro-fibrotic myofibroblasts.

![S100a4 haploinsufficiency enhances deposition of a mature Collagen matrix and reduced myofibroblast content.\
(**A**) ABH/OG and picrosirius red staining demonstrate an increase in mature collagen fibers (blue arrows) bridging the tendon ends in S100a4^GFP/+^ repairs compared to WT littermates (n = 3--4 per group) (\*) indicate sutures. (**B--D**) S100A4^GFP/+^ tendons expressed significantly more *Col1a1* mRNA (**B**), while transcript levels of *Col3a1* (**C**) and *Scx* (**D**) were unaffected by S100a4 haploinsufficiency. (\*) indicates p\<0.05 (un-paired t-test), n = 3 per group. (E and F) *α-SMA* mRNA expression was significantly decreased in S100a4^GFP/+^ repairs (**E**) (n = 3 per group), while a substantial reduction in *α-SMA* protein expression was observed in S100a4^GFP/+^, relative to WT, using immunofluorescence (**F**). White arrows indicate areas of α-SMA^+^ cells in the healing tissue, yellow arrowheads denote α-SMA staining of vessels, blue boxes indicate location of higher magnification images.](elife-45342-fig3){#fig3}

S100a4 modulates macrophage content and function {#s2-4}
------------------------------------------------

Given the fibrotic nature of scar-mediated tendon healing, and the ability of macrophages to modulate multiple aspects of the fibrotic process ([@bib18]; [@bib34]; [@bib56]; [@bib57]), we examined changes in macrophage content and polarization during the proliferative phase of healing in WT and S100a4^GFP/+^ mice. While an apparent reduction in F4/80^+^ macrophages was observed in S100a4^GFP/+^ repairs, relative to WT at D14 (white arrows, [Figure 4A](#fig4){ref-type="fig"}), no differences in the F4/80^+^ percent area were observed between genotypes ([Figure 4D](#fig4){ref-type="fig"}), likely due to the reduced area of scar tissue. In terms of polarization, fewer iNOS^+^ (M1 marker) macrophages were observed in S100a4^GFP/+^ repairs at D14 ([Figure 4B](#fig4){ref-type="fig"}), while a trending decrease in the iNOS^+^ percent area was also observed (p=0.08) ([Figure 4D](#fig4){ref-type="fig"}). Expression of the M2 macrophage marker IL1ra was not different between WT and S100a4^GFP/+^ at D14 ([Figure 4C](#fig4){ref-type="fig"}), and no difference in IL1ra^+^ percent area was observed ([Figure 4D](#fig4){ref-type="fig"}). Taken together, these data suggest that S100a4 haploinsufficiency may suppress macrophage recruitment or retention during tendon healing, and result in a less pro-inflammatory macrophage environment.

![S100a4 haploinsufficiency alters the macrophage response to tendon injury.\
(**A**) F4/80 staining demonstrates decreased macrophage content in the healing tendon of S100a4^GFP/+^ repairs at D14. White arrows identify concentrated areas of macrophages. (**B**) Expression of the M1 macrophage marker iNOS is markedly reduced in S100a4^GFP/+^ repairs at D14. (**C**) Expression of the M2 macrophage marker IL1ra is not different between WT and S100a4^GFP/+^ repairs at D14. Tendon ends are outlined in white, scar tissue is outlined in yellow, blue boxes indicate location of higher magnification images (n = 4 per group). (**D**) The percent area of F4/80^+^, iNOS^+^ and IL1ra^+^ staining, normalized to tissue area was quantified (n = 4) (un-paired t-test).](elife-45342-fig4){#fig4}

To begin to define the S100a4^+^ cell population(s) during healing, and to determine if macrophages express S100a4 during tendon healing, we labeled macrophages (Csf1r^Lin+^) and assessed overlapping expression of S100a4 (S1004-GFP^promoter+^). At D3 post-surgery there were many Csf1r^Lin+^; S100a4GFP^promoter+^ cells (white arrows, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), however there was a large proportion of cells that were only Csf1r^Lin+^ or S100a4-GFP^promoter+^. By D14 a few Csf1r^Lin+^; S100a4GFP^promoter+^ cells were observed (white arrows, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), however, this population was markedly reduced relative to D3. Taken together these data suggest that additional populations of cells express S100a4 during tendon healing, and that the predominant role for S100a4^+^ macrophages may be during the early phases of healing.

To determine the effects of exogenous S100a4 and S100a4 haploinsufficiency on macrophages in vitro, primary bone marrow derived macrophages (BMDMs) were isolated from C57BL/6J, S100a4^GFP/+^ and WT mice. S100a4 recombinant protein (S100a4-RP) treatment enhanced C57BL/6J BMDM migration, relative to vehicle-treated cells, with a significant increase at the highest dose of 1000 ng/mL S100a4-RP ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). No changes in macrophage migration were observed between vehicle-treated WT and S100a4^GFP/+^ macrophages. In addition, treatment with 50 ng/mL and 1000 ng/mL S100a4-RP enhanced macrophage migration in both WT and S100a4^GFP/+^ cells, relative to vehicle-treated cells ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}), suggesting that S100a4 haploinsufficiency in macrophages does not alter migration ability, or responsiveness to S100a4, and indicating that S100a4 modulates macrophage migration via cell non-autonomous effects.

S100a4-RP treatment of primary macrophages had a variable impact on polarization {#s2-5}
--------------------------------------------------------------------------------

Expression of the M1 markers *iNOS* and *CD64* were significantly up-regulated in a dose-dependent manner following S100a4-RP treatment of C57BL/6J BMDMs, while *TNFα* was downregulated and no change was observed in *CD86* expression ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). M2 markers *Arg1* and *IL1ra* were significantly up-regulated with higher doses of S100a4-RP, while *CD163* was down-regulated and no change in *CD206* expression was observed in C57BL/6J BMDMs ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). No differences in macrophage polarization were observed in vehicle-treated WT and S100a4^GFP/+^ BMDMs, and in contrast to the C57BL/6J BMDMs, S100a4-RP (1000 ng/mL) treatment had minimal effects on M1 or M2 polarization ([Figure 4---figure supplement 2E and F](#fig4s2){ref-type="fig"}).

Given that not all S100a4-GFP^promoter+^ cells are Csf1r^Lin+^ during healing and that resident tendon cells express S100a4 ([Figure 1E](#fig1){ref-type="fig"}), we also examined the cell autonomous effects of S100a4 haploinsufficiency in primary tendon cells. A significant 50% reduction in *S100a4* expression was confirmed in S100a4^GFP/+^ tenocytes, while no significant differences in tenogenic marker expression (*Scx*, *Tnmd*, *Mkx*) or matrix gene expression (*Col1a1*, *Col3a1*, *Fn*) were observed between WT and S100a4^GFP/+^ tendon cells ([Figure 4---figure supplement 3A and B](#fig4s3){ref-type="fig"}). In addition, no changes in proliferation were observed between WT and S100a4^GFP/+^ tenocytes ([Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"}). To assess potential changes in migration we used a scratch wound assay. No changes in wound closure were observed between genotypes between 0--12 hr, however, trending improvements in closure were observed at 8 hr (p=0.059) and 12 hr (p=0.08) in S100a4^GFP/+^ tendon cells. By 24 hr there was a significant increase in percent wound closure in S100a4^GFP/+^ tendon cells, relative to WT (p=0.017) ([Figure 4---figure supplement 3D](#fig4s3){ref-type="fig"}), suggesting that S100a4 may modulate tendon cell migration through a cell autonomous process.

Inhibition of S100a4 signaling, via antagonism of RAGE improves tendon healing {#s2-6}
------------------------------------------------------------------------------

Considering that S100a4 haploinsufficiency improves tendon healing, and S100a4 can function as an extracellular signaling molecule to drive fibrotic progression ([@bib33]; [@bib54]; [@bib59]), we next examined expression of the putative S100a4 receptor, RAGE (Receptor for Advanced Glycation Endproducts) ([@bib14]; [@bib19]; [@bib46]). RAGE expression was observed throughout the scar tissue during tendon healing, with abundant co-localization of S100a4 and RAGE ([Figure 5A](#fig5){ref-type="fig"}). Consequently, we investigated the feasibility of inhibiting S100a4 signaling via disruption of S100a4-RAGE interaction using RAGE antagonist peptide (RAP) ([@bib3]). In vivo, RAP treatment ([Figure 5B](#fig5){ref-type="fig"}) significantly improved measures of gliding function relative to vehicle treated controls, with a 41% increase in MTP Flexion Angle (p=0.008) ([Figure 5C](#fig5){ref-type="fig"}), and a 39% decrease in Gliding Resistance (p=0.007) ([Figure 5D](#fig5){ref-type="fig"}). No differences in maximum load at failure (p=0.57) and stiffness (p=0.30) were observed between groups ([Figure 5E,F](#fig5){ref-type="fig"}). These data suggest that inhibition of S100a4-RAGE recapitulates the improvements in gliding function seen with S100a4 haploinsufficiency but is insufficient to improve mechanical properties.

![Inhibition of S100a4 signaling via RAGE antagonism improves tendon healing.\
(**A**) Co-immunofluorescence demonstrated co-localization of S100a4 and its putative receptor RAGE in the healing tendon (n = 3). (**B**) C57Bl/6J mice were treated with either RAP or vehicle, via i.p. injection from D5-10 post-surgery, and harvested at D14 for functional testing. (**C--F**) At D14 RAP treatment significantly improved measures of gliding function relative to vehicle, with a (**C**) significant increase in MTP Flexion Angle, and (**D**) a significant decrease in Gliding Resistance. No change in (**E**) Max load at failure, or (**F**) Stiffness was observed between treatments (n = 13 per group). (\*\*) indicates p\<0.01 between treatments (un-paired t-test).](elife-45342-fig5){#fig5}

S100a4^+^ cell ablation results in aberrant matrix deposition during tendon healing {#s2-7}
-----------------------------------------------------------------------------------

While S100a4 haploinsufficiency and inhibition of S100a4 signaling improves tendon healing, S100a4 can also function in a cell-autonomous manner ([Figure 4---figure supplement 3D](#fig4s3){ref-type="fig"}; [@bib11]). To determine the effects of S100a4^+^ cell ablation on tendon healing, we depleted proliferating S100a4^+^ cells from D5-10 post-surgery (immediately preceding peak *S100a4* expression) using S100a4-thymidine kinase (S100a4-TK) mice ([Figure 6A](#fig6){ref-type="fig"}). Depletion of S100a4^+^ cells from D5-10 resulted in a significant 91% reduction in *S100a4* mRNA expression at D10 (p\<0.001) ([Figure 6B](#fig6){ref-type="fig"}), and a substantial reduction in S100a4 protein expression, relative to WT at D14 ([Figure 6C](#fig6){ref-type="fig"}). Functionally, slight but non-significant improvements in gliding function were observed in S100a4-TK (D5-10), relative to WT ([Figure 6D and E](#fig6){ref-type="fig"}). However, max load at failure was significantly decreased by 43% (p=0.02) ([Figure 6F](#fig6){ref-type="fig"}), while stiffness was unchanged ([Figure 6G](#fig6){ref-type="fig"}). Morphologically, S100a4-TK (D5-10) tendons healed with thinner, more acellular bridging scar tissue between the native tendon ends, compared to the larger, more cellular granulation tissue in WT repairs ([Figure 6H](#fig6){ref-type="fig"}). Picrosirius staining demonstrated a substantial reduction in bridging ECM in S100a4-TK (D5-10) repairs, relative to WT ([Figure 6I](#fig6){ref-type="fig"}). In contrast to this, qPCR revealed significant increases in ECM proteins *Col1a1* (3.9-fold, p=0.04) ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) and *Col3a1* (1.9-fold, p=0.033) ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}) mRNA expression in S100a4-TK (D5-10) mice. Additionally, significant decreases in the tenogenic transcription factor *Scx* (1.75-fold, p=0.04), and the myofibroblast marker α-SMA (9-fold, p=0.0003) were observed in S100a4-TK (D5-10), relative to WT ([Figure 6---figure supplement 1C & D](#fig6s1){ref-type="fig"}). Consistent with this, and the phenotype in S100a4^GFP/+^ repairs, α-SMA staining was markedly reduced in S100a4-TK (D5-10) repairs, relative to WT ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), as was total macrophage content ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Taken together, S100a4-cell depletion alters normal matrix deposition during tendon healing, leading to pronounced morphological changes in the scar tissue and a loss of overall strength, while recapitulating the changes in myofibroblast and macrophage populations observed in S100a4^GFP/+^ repairs.

![Delayed depletion of S100a4^+^cells impairs restoration of mechanical properties and alters matrix deposition.\
(**A**) WT and S100a4-TK mice were treated twice daily with ganciclovir (GCV) from D5-10 post-surgery. (**B**) S100a4^+^ cell depletion results in a 91% reduction in *S100a4* mRNA at D10 post-surgery (n = 3). (**C**) A substantial reduction in S100a4 protein expression was observed S100a4-TK repairs, relative to WT. Tendon is outlined in blue, scar tissue is outlined in black and (\*) identify sutures (n = 4). (**D--G**) At D14 no change in MTP Flexion Angle (**D**) and Gliding Resistance (**E**) were observed between WT and S100a4-TK repairs. (**F**) Max load at failure was significantly reduced following S100a4-cell depletion, while no change in Stiffness was observed (**G**) (n = 7--10), (\*\*) indicates p\<0.01 (un-paired t-test). (**H and I**) Morphologically, (**H**) ABH/OG and (**I**) Picrosirius staining demonstrate reduced matrix deposition bridging the tendon ends in the S100a4-TK repairs, relative to WT. (\*) Indicates sutures.](elife-45342-fig6){#fig6}

We then investigated the effects of continuous S100a4^+^ cell depletion (D1-14) on healing ([Figure 7A](#fig7){ref-type="fig"}). In contrast to depletion from D5-10, depletion from D1-14 significantly reduced MTP Flexion Angle (−53%, p=0.0003) ([Figure 7B](#fig7){ref-type="fig"}), and increased gliding resistance (+187%, p\<0.001) ([Figure 7C](#fig7){ref-type="fig"}), indicating impairment of normal gliding function with sustained S100a4^+^ cell depletion. Consistent with D5-10 depletion, depletion from D1-14 reduced mechanical properties, with a 43% decrease in max load (p=0.025) ([Figure 7D](#fig7){ref-type="fig"}), and a 49% decrease in stiffness (p=0.0078) ([Figure 7E](#fig7){ref-type="fig"}).

![Sustained ablation of S100a4^+^impairs restoration of gliding function and mechanical properties.\
(**A**) WT and S100a4-TK mice were treated with GCV from D1-14 post-surgery to ablate proliferating S100a4^+^ cells. At D14 (**B**) MTP Flexion Angle was significantly reduced, and (**C**) Gliding Resistance was significantly increased in S100a4-TK repairs, relative to WT. (**D**) A non-significant decrease in Max load at failure and (**E**) a significant reduction in Stiffness were observed in S100a4-TK repairs (n = 8--11). (\*) indicates p\<0.05, (\*\*) indicates p\<0.01 (un-paired t-test).](elife-45342-fig7){#fig7}

S100a4-lineage cells represent differentiated a-SMA myofibroblasts in the scar tissue of healing tendon {#s2-8}
-------------------------------------------------------------------------------------------------------

Examination of S100a4^GFP/+^ and S100a4-TK (D5-10) healing tendons demonstrate dramatically reduced myofibroblast content, suggesting potential interplay between S100a4^+^ cells and myofibroblasts. The relationship between S100a4 and pro-fibrotic myofibroblasts is controversial and likely tissue-dependent, with conflicting reports of myofibroblast fate for S100a4^+^ cells ([@bib22]; [@bib29]; [@bib39]; [@bib53]). To understand the relationship between these cell populations during tendon healing we examined α-SMA expression in both S100a4-lineage cells and cells actively expressing S100a4 (S100a4-GFP^promoter+^). S100a4-Cre; Ai9 mice demonstrate that \~ 65% of α-SMA^+^ myofibroblasts at D14 post-surgery are derived from S100a4-lineage, as shown by co-localization ([Figure 8A](#fig8){ref-type="fig"}, arrows, [Figure 8C](#fig8){ref-type="fig"}). In contrast, very few (\~16%) S100a4-GFP^promoter+^ cells demonstrated co-localization with α-SMA ([Figure 8B and C](#fig8){ref-type="fig"}). Taken together these data suggest that S100a4-lineage cells lose S100a4 expression during the transition to α-SMA^+^ myofibroblasts.

![S100a4-lineage cells lose S100a4 expression during the transition to α-SMA^+^myofibroblasts.\
(**A**) Co-localization of Red Fluorescent Protein (S100a4^Lin+^ cells; red) and the myofibroblast marker α-SMA (white) demonstrated abundant co-localization (yellow arrows) during tendon healing. (**B**) Minimal co-localization of α-SMA (white) and cells actively expressing S100a4 (S100a4-GFP^promoter+^; green) was observed during healing (n = 3). (**C**) Quantification of the percent α-SMA^+^ area that is also S100a4^Lin+^ (red and white bar) or S100a4-GFP^promoter+^ (green and white bar) at D14 (n = 3--4 per group) (\*\*) indicates p\<0.01 between groups (un-paired t-test). (**D**) Schematic representation of the proposed cell non-autonomous signaling functions of S100a4 in fibrotic healing, as well as cell fate of S100a4-lineage cells. The identities and discrete functions of specific populations of S100a4^+^ cells remains to be determined.](elife-45342-fig8){#fig8}

Discussion {#s3}
==========

Consistent with the role of S100a4 as a key driver of fibrosis ([@bib8]; [@bib24]; [@bib27]; [@bib54]), we have demonstrated that S100a4 promotes scar-mediated tendon healing primarily via cell-non-autonomous extracellular signaling. Further, we have shown that S100a4 haploinsufficiency drives regenerative tendon healing and depletion of S100a4^+^ cells disrupts re-acquisition of mechanical properties. Interestingly, the effects of S100a4^+^ cell depletion on functional metrics were time-dependent, suggesting a period of optimal S100a4 inhibition. Mechanistically, S100a4 haploinsufficiency and S100a4^+^ cell depletion modulates macrophage content, suggesting the ability of S100a4 to regulate the inflammatory milieu during tendon healing. In addition, S100a4-lineage cells lose expression of S100a4 to become α-SMA^+^ pro-fibrotic myofibroblasts, which are likely involved in both restoration of matrix integrity and deposition of excess ECM. Taken together, these data establish S100a4 haploinsufficiency as a novel model of regenerative, mechanically superior tendon healing, and identify S100a4 as a potent anti-fibrotic therapeutic candidate to improve tendon healing.

S100a4 lacks enzymatic activity and functions predominantly through the regulation and interaction with other proteins. While the intracellular functions of S100a4 are not well-characterized, the extracellular signaling functions of S100a4 include regulation of multiple cellular processes important in fibrosis including motility ([@bib5]; [@bib40]), differentiation ([@bib35]; [@bib41]; [@bib48]) and survival ([@bib41]). S100a4 protein levels are strongly correlated with idiopathic pulmonary fibrosis ([@bib29]), and S100a4 has been suggested as a potential fibrotic biomarker in the liver ([@bib9]). Consistent with this, we see highest S100a4 expression immediately prior to the period of peak scar formation during tendon healing. The therapeutic potential of targeting S100a4 has been well established in the lung, with decreased fibrotic progression following treatment with an S100a4 neutralizing antibody ([@bib29]), and pharmacological inhibition of S100a4 ([@bib61]). Moreover, [@bib54] demonstrated that deletion of S100a4 prevented bleomycin-induced skin fibrosis. Consistent with these studies, we demonstrate that S100a4 haploinsufficiency is sufficient to attenuate scar-mediated tendon healing and promotes a more regenerative healing response. More specifically, S100a4^GFP/+^ repairs demonstrate suppression of multiple components of the fibrotic cascade including macrophage content, myofibroblasts, as well as an altered ECM balance toward a mature tendon composition (*Col1a1* \> *Col3a1*).

Macrophages play an essential role in wound healing, and S100a4 is a potent chemokine and regulator of macrophage chemotaxis. Bone marrow-derived macrophages from S100a4^-/-^ mice display defects in chemotactic motility and impaired recruitment to the site of inflammation ([@bib28]). In contrast, we show that S100a4 haploinsufficient primary BMDMs do not exhibit deficits in migration relative to WT, and that S100a4^GFP/+^ cells are responsive to the pro-migration effects of exogenous S100a4. Importantly, it is unknown whether S100a4^-/-^ macrophages also increase migration in response to exogenous S100a4. Answering this question will help clarify whether the cell non-autonomous effects of S100a4 on macrophages are dependent on a minimum level of S100a4 expression in macrophages. Taken together, the enhanced migration of BMDMs in response to S100a4, and the reduced macrophage content in S100a4 haploinsufficient and S100a4^+^ cell-depleted repairs, suggests a potential role for extracellular S100a4 in macrophage recruitment during tendon healing. Moreover, while RAGE can be expressed on a variety of cell types, macrophages have been shown to be the primary source of RAGE in the context of pathology ([@bib16]; [@bib45]; [@bib50]; [@bib51]). Therefore, in addition to decreasing the macrophage content, and thereby RAGE^+^ cells, S100a4^GFP/+^ may also suppress signaling via direct down-regulation of RAGE. RAGE expression is highly dependent on ligand concentration ([@bib6]), and we have decreased *S100a4* expression by 50%, implying down-regulation of the entire S100a4-RAGE-macrophage axis in S100a4^GFP/+^ mice. Interestingly, although inhibition of S100a4-RAGE with RAP recapitulates the improvements in gliding function observed in S100a4^GFP/+^ repairs, it is insufficient to improve mechanical properties. This suggests that S100a4 may regulate restoration of mechanical properties through mechanisms independent of RAGE. In addition to RAGE, extracellular S100a4 acts as a ligand for TLR4 ([@bib7].), and has been shown to interact with EGFR ligands ([@bib26]), Heparan Sulfate Proteoglycans ([@bib25]), and cell surface Annexin 2 ([@bib43]) to modulate signaling. Understanding the potential RAGE-independent mechanisms of S100a4 signaling will be an important aspect of future research. Importantly, while RAP treatment inhibits S100a4-RAGE signaling, it also blocks binding of other RAGE ligands. In addition, there are likely time-dependent effects of S100a4-RAGE signaling. Since RAP treatment was limited to a single timing regimen it is unknown how inhibition of RAGE signaling at other time-points, or in a sustained fashion may affect healing. Future studies to specifically inhibit S100a4 signaling, and to examine the time-dependent effects of S100a4-RAGE inhibition are needed.

S100a4^+^ cell depletion has shown great efficacy in managing fibrotic progression in the peritoneum ([@bib36]), and kidney ([@bib23]). In contrast, depletion of S100a4^+^ cells impairs tendon healing, particularly when S100a4^+^ cells are depleted from D1-14. These opposing effects may be due to fundamental differences in the functions of affected tissues, with tendon being a mechanical, load-bearing tissue. Interestingly, the more pronounced negative effect of cell depletion from D1-14, relative to D5-10 depletion may be explained by suppression of the acute inflammatory phase. Anti-inflammatory administration during the acute inflammatory phase of tendon healing is effective at reducing scar formation, but causes marked reductions in mechanical properties ([@bib12]; [@bib13]; [@bib20]). Taken together, these data further support the importance of timing treatment to modulate fibrotic tendon healing, particularly as it relates to S100a4 inhibition, as noted above.

One of the main controversies surrounding S100a4^+^ cells is their potential to become α-SMA^+^ myofibroblasts. Osterreicher *et al*., demonstrated that neither actively expressing S100a4^+^ cells or S100a4^Lin+^ cells express α-SMA during lung fibrosis ([@bib37].), and additional work demonstrates that S100a4^+^ bone marrow cells do not express α-SMA ([@bib10]). In contrast, dermal fibroblasts are positive for expression of both S100a4 and α-SMA ([@bib37]) and [@bib9] demonstrate that S100a4 treatment increases α-SMA expression, while α-SMA^+^ cells decrease with S100a4-cell depletion in a model of liver fibrosis. Using a similar combination of S100a4-lineage tracing and active S100a4 expression analyses as in [@bib37], we demonstrate that S100a4^Lin+^ cells become α-SMA^+^, and that the α-SMA^+^ population is largely negative for S100a4. These data not only define a terminal myofibroblast fate for many S100a4-lineage cells during tendon healing, but further support the concept of exquisite cell and tissue specificity of S100a4 signaling.

In addition to terminal cell fate, the origin of S100a4^+^ cells are unclear. Osterreicher *et al*., demonstrate that bone marrow derived cells (BMDCs) represent the main source of S100a4 during liver fibrosis ([@bib37]), and S100a4^+^ BMDCs have been shown to migrate to the site of neointima formation following vein grafting ([@bib10]). While we have not traced S100a4^+^ BMDCs in this study, we have previously shown specific recruitment of BMDCs to the healing tendon ([@bib31]), and we also see S100a4^Lin+^ and S100a4-GFP^promoter+^ populations in the tendon without injury. To begin to define the S100a4^+^ cells during healing we examined S100a4 expression in Csf1r^Lin+^ macrophages as Osterreicher et al., suggest a subpopulation of inflammatory macrophages express S100a4. Somewhat surprisingly, only a small proportion of macrophages express S100a4 at D3 and D14 post-surgery. In addition to macrophages, we also observe S100a4 expression in resident tendon cells prior to injury, however, the specific function of tendon-derived S100a4 is unclear. Taken together, the cellular contributors to S100a4 expression and therefore scar-mediated healing are clearly complex and multi-faceted. Future studies are needed to delineate the relative contributions of S100a4 from different cell populations to the scar-mediated tendon healing process, using cell-type specific, inducible Cre lines.

While we clearly identify S100a4 haploinsufficiency as a model of regenerative tendon healing, there are several limitations, in addition to those discussed above, that must be considered. First, we have not investigated whether this signaling paradigm is conserved in other tendons. However, we do observe S100a4^+^ cells in the Achilles tendon at homeostasis and expansion of this population following injury. Since scar-mediated healing is consistent between tendons ([@bib44]), this reinforces the potential application of this approach to improve healing in multiple tendons. Moreover, the surgical repair and healing model used in these studies does not fully recapitulate the clinical scenario as no rehabilitation is conducted, and there is clear evidence of the beneficial effects of physical therapy to improve healing outcomes ([@bib47]). Second, the long-term effects of diminished S100a4 signaling are unknown, as we have only examined healing at D14. Therefore, it will be important to define the long-term effects of S100a4 haploinsufficiency or pharmacological inhibition on the healing process, including assessment of material properties, which were not measured in the current study. However, peak expression of *S100a4* at D10 post-surgery suggests the prime effects of S100a4 may occur during the early inflammatory-proliferative phases of healing. Moreover, the time-dependent effects of S100a4-cell depletion suggest there is likely an optimal therapeutic window for S100a4 inhibition, which will be examined in future studies. Finally, we have not delineated between the effects of S100a4 expression in resident tendon cells relative to expression in extrinsic cells, and how the cell origin of S100a4 may dictate the effects on healing.

Restoring satisfactory function following tendon injury has remained an intractable clinical problem for decades ([@bib49]). To our knowledge this is the first model of regenerative tendon healing in transgenic mice, defined by improvements in range of motion and mechanics. These data will inform future work to define the pathways down-stream of S100a4-RAGE, rigorously determine the time-dependent effects of S100a4 inhibition, define and delineate the functions of all S100a4^+^ cell populations, and identify the cues that drive the transition of S100a4-lineage cells to myofibroblasts. More directly however, these studies define the tremendous potential of inhibition of S100a4 signaling as a therapeutic approach to promote regenerative tendon healing.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                       Designation                                               Source or reference                                                     Identifiers                                                              Additional\
  (species) or\                                                                                                                                                                                                                                  information
  resource                                                                                                                                                                                                                                       
  ----------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------
  Genetic reagent (*Mus. musculus*)   B6.Cg-Tg(S100a4-EGFP)M1Egn/YunkJ (S100A4-GFP^promoter^)   Jackson Laboratory                                                      Stock \#: 012893\                                                        
                                                                                                                                                                        RRID: [MGI:4819362](https://scicrunch.org/resolver/MGI:4819362)          

  Genetic reagent (*M. musculus*)     B6.Cg-Tg(S100a4-TK)M31Egn/YunkJ (S100a4-TK)               Jackson Laboratory                                                      Stock \#: 012902\                                                        
                                                                                                                                                                        RRID:[MGI:4454768](https://scicrunch.org/resolver/MGI:4454768)           

  Genetic reagent (*M. musculus*)     B6.129S6-S100a4tm1Egn/YunkJ (S100a4^GFP/+^)               Jackson Laboratory                                                      Stock \#: 012904\                                                        
                                                                                                                                                                        RRID:[MGI:4819358](https://scicrunch.org/resolver/MGI:4819358)           

  Genetic reagent (*M. musculus*)     BALB/c-Tg(S100a4-cre)1Egn/YunkJ (S100a4-Cre)              Jackson Laboratory                                                      Stock \#: 012641\                                                        
                                                                                                                                                                        RRID:[MGI:4454332](https://scicrunch.org/resolver/MGI:4454332)           

  Genetic reagent (*M. musculus*)     B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (ROSA-Ai9)      Jackson Laboratory                                                      Stock \#: 007909\                                                        
                                                                                                                                                                        RRID:[MGI:3809523](https://scicrunch.org/resolver/MGI:3809523)           

  Genetic reagent (*M. musculus*)     Tg(Csf1r-Mer-iCre-Mer)1Jwp (Csf1r-iCre)                   Jackson Laboratory                                                      Stock \#: 019098\                                                        
                                                                                                                                                                        RRID:[IMSR_JAX:019098](https://scicrunch.org/resolver/IMSR_JAX:019098)   

  Genetic reagent (*M. musculus*)     C57BL/6J                                                  Jackson Laboratory                                                      Stock \#: 000664\                                                        
                                                                                                                                                                        RRID:[MGI:3028467](https://scicrunch.org/resolver/MGI:3028467)           

  Antibody                            anti-RAGE (mouse monoclonal)                              Santa Cruz Biotechnology                                                Cat. \#: sc-365154\                                                      1:100
                                                                                                                                                                        RRID:[AB_10707685](https://scicrunch.org/resolver/AB_10707685)           

  Antibody                            anti-F4/80 (goat polyclonal)                              Santa Cruz Biotechnology                                                Cat. \#: sc-26642\                                                       1:500
                                                                                                                                                                        RRID:[AB_2098333](https://scicrunch.org/resolver/AB_2098333)             

  Antibody                            anti-GFP (goat polyclonal)                                Abcam                                                                   Cat. \#: ab6673\                                                         1:5000
                                                                                                                                                                        RRID:[AB_305643](https://scicrunch.org/resolver/AB_305643)               

  Antibody                            anti-RFP (rabbit polyclonal)                              Abcam                                                                   Cat. \#: ab62341\                                                        1:500
                                                                                                                                                                        RRID:[AB_945213](https://scicrunch.org/resolver/AB_945213)               

  Antibody                            anti-S100a4 (rabbit monoclonal)                           Abcam                                                                   Cat. \#: ab197896\                                                       1:20000
                                                                                                                                                                        RRID:[AB_2728774](https://scicrunch.org/resolver/AB_2728774)             

  Antibody                            anti-iNOS (rabbit polyclonal)                             Abcam                                                                   Cat. \#: ab15323\                                                        1:100
                                                                                                                                                                        RRID: [AB_301857](https://scicrunch.org/resolver/AB_301857)              

  Antibody                            Anti-ILIRa (rabbit monoclonal)                            Abcam                                                                   Cat. \#: ab124962\                                                       1:10000
                                                                                                                                                                        RRID:[AB_11130394](https://scicrunch.org/resolver/AB_11130394)           

  Antibody                            anti-alpha-SMA-Cy3 (mouse monoclonal)                     Sigma-Aldrich                                                           Cat. \#: C6198\                                                          1:250
                                                                                                                                                                        RRID: [AB_476856](https://scicrunch.org/resolver/AB_476856)              

  Antibody                            Donkey anti-rabbit AlexaFluor594 secondary                Jackson ImmunoResearch                                                  Cat. \#: 711-585-152\                                                    1:200
                                                                                                                                                                        RRID: [AB_2340621](https://scicrunch.org/resolver/AB_2340621)            

  Antibody                            Donkey anti-rabbit 647 secondary                          Jackson ImmunoResearch                                                  Cat. \#: 711-605-152\                                                    1:200
                                                                                                                                                                        RRID: [AB_2492288](https://scicrunch.org/resolver/AB_2492288)            

  Antibody                            Donkey anti-rabbit Rhodamine-Red-X                        Jackson ImmunoResearch                                                  Cat. \#: 711-296-152\                                                    1:100
                                                                                                                                                                        RRID:[AB_2340614](https://scicrunch.org/resolver/AB_2340614)             

  Antibody                            Donkey anti-goat 488 secondary                            Jackson ImmunoResearch                                                  Cat. \#: 705-546-147\                                                    1:200
                                                                                                                                                                        RRID: [AB_2340430](https://scicrunch.org/resolver/AB_2340430)            

  Antibody                            Goat anti-mouse AlexaFluor488 secondary                   ThermoFisher                                                            Cat. \#: A11029\                                                         1:1000
                                                                                                                                                                        RRID:[AB_138404](https://scicrunch.org/resolver/AB_138404)               

  Chemical compound, drug             Nucleoside analog ganciclovir (GCV)                       TSZCHEM                                                                 Cat \#: 82410-32-0                                                       75 mg/kg

  Peptide, recombinant protein        RAGE Antagonist Peptide (RAP)                             MilliporeSigma                                                          Cat. \#: 553031                                                          100 ug (peptide)

  Peptide, recombinant protein        Human S100a4 Recombinant protein                          LSBio                                                                   Cat \#: G1305                                                            20--1000 ng/mL (recombinant protein)

  Commercial kit                      Rabbit polymer kit                                        Vector Laboratories                                                     Cat \#: MP-7401                                                          

  Software                            OlyVIA software                                           Olympus (<https://www.olympus-lifescience.com/en/support/downloads/>)   RRID:[SCR_016167](https://scicrunch.org/resolver/SCR_016167)             Version 2.9

  Software                            ImageJ software                                           ImageJ (<http://imagej.nih.gov/ij/>)                                    RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)             

  Software                            GraphPad Prism software                                   GraphPad Prism (<https://graphpad.com>)                                 RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)             Version 8.0.0
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ethics statement {#s4-1}
----------------

All animal studies were approved by the University of Rochester Committee for Animal Resources.

Mouse strains {#s4-2}
-------------

S100A4-GFP^promoter^ mice (\#012893), S100a4-TK (\#012902), S100a4^GFP/+^ (\#012904), S100a4-Cre (\#012641), ROSA-Ai9 (\#007909), Csf1r-iCre (\#019098), and C57BL/6J (\#000664) were acquired from The Jackson Laboratory (Bar Harbor, ME).

S100a4-GFP promoter mice contain a construct encoding EGFP under control of the S100a4 promoter sequence, resulting in green fluorescence in cells actively expressing S100a4 ([@bib24]). S100a4-TK mice contain a viral thymidine kinase gene downstream of the S100a4 promoter, and treatment with the nucleoside analog ganciclovir (GCV) halts DNA replication in proliferating cells expressing S100a4, resulting in apoptosis and S100a4^+^ cell ablation ([@bib23]). Mice were treated twice per day (i.p) with 75 mg/kg GCV. S100a4^GFP/+^ mice contain a GFP-encoding gene knocked into the exons 2--3 of the *S100a4* gene, resulting in a 50% reduction in S100a4 protein expression ([@bib58]). To determine whether macrophages express S100a4 during healing, Csf1r-iCre; Rosa-Ai9; S100a4-GFP^promoter^ mice were treated with Tamoxifen (Tmx; 100 mg/kg) to label Csf1r-lineage (Csf1r^Lin+^) cells. For samples harvested on D3, mice were treated with Tmx on D0-2 post-surgery. Mice harvested at D14 were treated with Tmx on D0-2 post-surgery, and every other day thereafter until harvest. Cells actively expressing S100a4 were labeled green (S100a4-GFP^promoter+^). For RAGE Antagonist Peptide (RAP) studies, C57BL/6J mice were treated with either 100 μg RAP or vehicle (0.5% bovine serum albumin in saline) via i.p. injection on D5-10 post-surgery.

Murine model of tendon injury and repair {#s4-3}
----------------------------------------

Male and female mice aged 10--12 weeks underwent complete transection and surgical repair of the flexor digitorum longus (FDL) tendon as previously described ([@bib2]). Mice were monitored and given analgesics post-operatively as needed.

RNA extraction and qPCR for in vivo studies {#s4-4}
-------------------------------------------

The tendon repair site was excised from the hind paw at D10 following injury, along with 1--2 mm of native tendon on either side. Three repairs were pooled, and RNA was extracted with TRIzol reagent (Life Technologies, Carlsbad CA). cDNA was generated with 500 ng of RNA using an iScript cDNA synthesis kit (BioRad, Hercules CA). Quantitative PCR was carried out with gene specific primers ([Table 1](#table1){ref-type="table"}), and expression normalized to *β-actin*. All experiments were done in biological triplicates and repeated twice (technical replicates).

10.7554/eLife.45342.019

###### qPCR Primer Sequences

  Gene                                 Sequence (5\'- \> 3\')     Reference
  ----------- ------------------------ -------------------------- ----------------
   *Actb*     Fwd                      AGATGTGCATCAGCAAGCAG       NM_007393.5
   Rev        GCGCAAGTTAGGTTTTGTCA                                
   *S100a4*   Fwd                      AAGCTGAACAAGACAGAGCTCAAG   NM_011311.2
   Rev        GTCCTTTTCCCCAGGAAGCTA                               
   *Fn*       Fwd                      CGAGGTGACAGAGACCACAA       NM_001276413.1
   Rev        CTGGAGTCAAGCCAGACACA                                
   *Tnmd*     Fwd                      TGTACTGGATCAATCCCACTCT     NM_022322.2
   Rev        GCTCATTCTGGTCAATCCCCT                               
   *Scx*      Fwd                      TGGCCTCCAGCTACATTTCT       NM_198885.3
   Rev        TGTCACGGTCTTTGCTGAAC                                
   *Mkx*      Fwd                      CACCGTGACAACCCGTACC        NM_177595.4
   Rev        GCACTAGCGTCATCTGCGAG                                
   *Col1a1*   Fwd                      GCTCCTCTTAGGGGCCACT        NM_007742.4
   Rev        CCACGTCTCACCATTGGGG                                 
   *Col3a1*   Fwd                      ACGTAGATGAATTGGGATGCAG     NM_009930.2
   Rev        GGGTTGGGGCAGTCTAGTG                                 
   *Acta2*    Fwd                      GAGGCACCACTGAACCCTAA       NM_007392.3
   Rev        CATCTCCAGAGTCCAGCACA                                
   *iNOS*     Fwd                      CAGAGGACCCAGAGACAAGC       NM_001313921.1
   Rev        TGCTGAAACATTTCCTGTGC                                
   *TNFa*     Fwd                      AACTGTAAGCGGGGCAATCA       NM_013693.3
   Rev        CCCCTTTCCTCCCAAACCAA                                
   *Cd86*     Fwd                      TCTCCACGGAAACAGCATCT       NM_019388.3
   Rev        CTTACGGAAGCACCCATGAT                                
   *Cd64*     Fwd                      TCCTTCTGGAAAATACTGACC      NM_010186.5
              Rev                      GTTTGCTGTGGTTTGAGACC       
   *Cd206*    Fwd                      CAGGTGTGGGCTCAGGTAGT       NM_008625.2
   Rev        TGTGGTGAGCTGAAAGGTGA                                
   *Arg1*     Fwd                      AGGAACTGGCTGAAGTGGTTA      NM_007482.3
   Rev        GATGAGAAAGGAAAGTGGCTGT                              
   *IL1ra*    Fwd                      GCATCTTGCAGGGTCTTTTC       NM_001159562.1
   Rev        GTGAGACGTTGGAAGGCAGT                                
   *Cd163*    Fwd                      TCCACACGTCCAGAACAGTC       NM_001170395.1
   Rev        CCTTGGAAACAGAGACAGGC                                

Assessment of gliding function and mechanical properties {#s4-5}
--------------------------------------------------------

Following sacrifice, the hindlimb was harvested at the knee. The medial side of the hindlimb was carefully dissected to free the FDL, and the proximal end was secured between two pieces of tape with cyanoacrylate. The distal tendon was loaded via the tape with weights ranging from 0 to 19 g, with digital images taken upon application of each weight. MTP Flexion Angle and Gliding Resistance were calculated as previously described ([@bib1]; [@bib21]; [@bib30]), with lower MTP Flexion Angle and higher Gliding Resistance corresponding to restricted range of motion and impaired gliding function. Following gliding testing, the FDL was released from the tarsal tunnel, and the proximal end of the tendon and the digits were secured in opposing custom grips on an Instron 8841 uniaxial testing system (Instron Corporation, Norwood, MA). The tendon was loaded until failure at a rate of 30 mm/minute ([@bib21]). Samples were excluded from analysis if the MTP Flexion Angle was less than 3° as dissection of samples below this threshold demonstrates consistent failure of the repair.

Histology, Immunohistochemistry and Immunofluorescence {#s4-6}
------------------------------------------------------

Following sacrifice, hind paws were dissected just above the ankle, and underwent routine processing for paraffin or frozen sectioning. Paraffin samples were fixed for 72 hr in 10% NBF, then decalcified for 2 weeks in 14% EDTA before processing. Three-micron sagittal sections were stained with Alcian Blue Hematoxylin/Orange G (ABH/OG) or picrosirius red stain (Polysciences Inc, Warrington PA). Frozen samples were fixed overnight, decalcified for 4 days, incubated in 30% sucrose (in PBS) overnight, and embedded in Cryomatrix (\#6769006, ThermoFisher, Waltham MA). Eight-micron sagittal sections on Cryofilm tape (Section-lab, Hiroshima, Japan) were cut on a Leica CM1860UV cryostat, and adhered to slides with 1% chitosan in 0.25% acetic acid.

Chromogen immunohistochemistry was performed on paraffin sections for S100a4 (1:20000, \#197896, Abcam, Cambridge MA), with a rabbit polymer kit (\#MP-7401, Vector Laboratories, Burlingame CA). Immunofluorescence was carried out with the following primary and secondary antibodies: RAGE (1:100, \#sc-365154, Santa Cruz Biotechnology, Dallas TX), with goat anti-mouse AlexaFluor488 secondary (1:1000, \#A11029, ThermoFisher, Waltham MA); F4/80 (1:500, \#sc-26642, Santa Cruz Biotechnology, Dallas TX) with a donkey anti-rabbit AlexaFluor594 secondary (1:200, \#711-585-152, Jackson ImmunoResearch, West Grove PA); iNOS (1:100, \#Ab15323, Abcam), with a Rhodamine-Red-X donkey anti-rabbit secondary (1:100, \#711-296-152, Jackson ImmunoResearch); IL1Ra (1:10000, \#Ab124962, Abcam), with a with a Rhodamine-Red-X donkey anti-rabbit secondary (1:100, \#711-296-152, Jackson ImmunoResearch); GFP (1:5000, \#ab6673, Abcam, Cambridge MA), with a donkey anti-goat 488 secondary (1:200, \#705-546-147, Jackson ImmunoResearch, West Grove PA); RFP (1:500, \#ab62341, Abcam, Cambridge MA), with a donkey anti-rabbit 647 secondary (1:200, \#711-605-152, Jackson ImmunoResearch, West Grove PA); and α-SMA-Cy3 (1:250, \#C6198 Sigma-Aldrich, St Louis MO). All slides were imaged with the Olympus slide scanner and processed with Olyvia software (Olympus, Waltham MA). Images were pseudo-colored using ImageJ software (v1.51j8, NIH). At least three animals were evaluated per genotype per time-point.

Quantification of fluorescence {#s4-7}
------------------------------

Slide scanned fluorescent images were analyzed with Visiopharm image analysis software v.6.7.0.2590 (Visiopharm, Hørsholm, Denmark) as previously described ([@bib1]). Briefly, the percent area coverage of endogenous fluorescence or immunofluorescent staining was quantified in a semi-automated fashion using a threshold classifier for each fluorescent channel. Regions of interest were drawn to include only tendon and scar tissue. Manual correction excluded quantification of staining in blood vessels, auto-fluorescent sutures and debris smaller than 10 μm^2^. Data are presented as the percent area of the region of interest that is positive for the appropriate fluorescent channel(s). Images were analyzed from 3 to 4 individual samples per genotype.

In Vitro Studies {#s4-8}
----------------

### Primary macrophage isolation {#s4-8-1}

Bone marrow derived primary macrophages (BMDM) were grown from the bone marrow of C57Bl/6J, S100a4^GFP/+^ and WT mice. Following sacrifice, femurs were flushed with ice-cold phosphate buffered saline (PBS, without Ca^2+^ /Mg^2+^). The cell suspension was strained through a 70 µm filter, resuspended in differentiation medium ([@bib55]) and plated at a concentration of 3 × 10^6^ cells per 10 cm plate. At D7 of differentiation, primary macrophages were re-plated as needed for experimental use. All BMDM experiments were conducted in biological triplicates with 2--4 technical replicates.

### Macrophage Migration assay {#s4-8-2}

Primary BMDMs were seeded at confluence in Oris 96-well plates (Platypus Technologies, Madison WI) with silicon stoppers inserted and incubated overnight. Plugs were removed, and cells washed once with PBS (with Ca^2+^ /Mg^2+^) prior to addition of treatment. Vehicle (0.5% Bovine Serum Albumin in PBS) or recombinant S100a4 protein (S100a4-RP) was added to wells at 20, 50, 200, 500, and 1000 ng/mL in quadruplicate, and cells allowed to migrate for 24 hr. Following migration, cells were gently washed with PBS and stained with NucBlue Live ReadyProbe (Life Technologies, Carlsbad CA). A detection mask was affixed to the bottom of the plate to obscure cells that had not migrated, and the plate read on a Synergy two plate reader (Biotek, Winooski VT) at 360ex/480em, and fluorescence normalized to vehicle treated cells.

### Assessment of in vitro macrophage polarization {#s4-8-3}

Primary BMDMs were seeded into 6-well plates at 85% confluence overnight. Cells were treated with either S100a4-RP (20--1000 ng/mL) or vehicle for 24 hr. Cells were lysed in Trizol (Life Technologies, Carlsbad CA), and RNA extracted using the RNeasy mini kit (Qiagen, Germantown MD). Quantitative PCR was performed with gene specific primers ([Table 1](#table1){ref-type="table"}) for markers of M1 (*iNOS*, *Tnfα*, *CD86*, *CD64*) and M2 (*CD206*, *Arg1*, *IL-1ra*, *CD163*) polarization, and data normalized expression in vehicle treated WT cells, and to *β-actin* expression.

### Primary tendon cell isolation {#s4-8-4}

FDL tendons (n = 4 per genotype) were aseptically excised, pooled, and collagenase digested (0.075% collagenase I; \#C6885, Sigma) in fibroblast grown medium-2 (FGM; \#CC-3132, Lonza, Basel, Switzerland) for one hour at room temperature with stirring. The collagenase mixture was then filtered (70 μM filter) and cells were pelleted, resuspended in FGM, and plated at 5,000 cells/cm^2^ in collagen-coated plates (rat tail collagen type 1, 5 μg/cm^2^; \#354236, Corning, Tewksbury, MA). Cell were maintained under standard culture conditions (37°C, 5% CO~2~, 90% humidity), with complete media exchanges every other day. Upon reaching 70% confluence, cells were passaged using 0.05% trypsin-EDTA (\#25300--054, Gibco, Waltham, MA).

### Tendon cell RNA isolation and qPCR {#s4-8-5}

Total RNA was isolated from tendon cells at passage 1, by column purification (TRIzol Reagent; \#15596026, Fisher Scientific; Direct-zol RNA Microprep kit, \#R2061, Zymo Research) and converted to cDNA (qScript; \#84034, Quantabio, Beverly, MA). Primers for murine genes of interest were designed ([Table 1](#table1){ref-type="table"}) (Primer Express, Applied Biosystems; [Table 1](#table1){ref-type="table"}), validated, and used for qPCR (PerfeCTa SYBR Green; \#84069, Quantabio, CFX Connect Real-Time System; Bio-Rad). Data were normalized to β*-*actin (*Actb*) and expression in WT.

### Tendon cell proliferation assay {#s4-8-6}

Tendon cells (passage 2) were plated onto collagen-coated black 96 well plates at 5,000 cells/cm^2^ in FGM. Cell proliferation was evaluated every 24 hr for 4 days using the CellTiter-Glo Luminescent Cell Viability Assay (\#PR-G7570, Fisher Scientific) in quadruplicate. Cell proliferation is shown relative to the average initial luminescent read for each genotype.

### Tendon cell scratch wound closure assay {#s4-8-7}

Tendon cells (passage 2) were plated into collagen-coated 24 well plates in duplicate at 5,000 cells/cm^2^ in FGM. At confluence, scratches were created in the cell monolayer using a p200 pipet tip. Monolayers were rinsed 3x with dPBS to remove debris and covered with fresh FGM containing 0.5% FBS. Triplicate images were taken at 0, 3, 5, 8, 12, and 24 hr to evaluate cell migration (ImageJ; National Institutes of Health).

### Statistical analyses and animal stratification {#s4-8-8}

Statistically significant differences between genotypes or treatments in in vitro and in vivo studies were assessed by unequal variance un-paired t-test, with the following exceptions: The *S100a4* qPCR time-course was analyzed by one-way ANOVA, followed by Tukey's multiple comparisons test. The BMDM migration and polarization data, as well as the tenocyte proliferation and scratch wound assay were analyzed by two-way ANOVA with Sidak's multiple comparison test. All analyses were conducted using GraphPad Prism software (v8.0.0, La Jolla CA). Data are presented as mean ± SD. p values ≤ 0.05 were considered significant, with the following conventions: \*=p ≤ 0.05, \*\*=p ≤ 0.01, and \*\*\*=p ≤ 0.001.: Mice were randomly allocated to specific experimental outcome metrics prior to surgery. Analysis of subjective quantitative data (MTP Flexion Angle, Gliding Resistance) were done in a blinded manner. Outlier data points for tested for using GraphPad Prism software using the ROUT method, and the Q value set at 1%, however no outliers were identified in any quantitative data sets.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Cell non-autonomous functions of S100a4 drive fibrotic tendon healing\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Clifford J Rosen as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Harry Dietz as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Stavros Thomopoulos (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

All three reviewers were positively inclined and felt the data are novel and potentially important. You have shown that S100a4 drives fibrotic tendon healing, possibly through a cell non-autonomous process; S100a4 haploinsufficiency promoted regenerative tendon healing and inhibition of S100a4 via antagonism of its putative receptor, RAGE, decreased scar formation. Also knock-down of S100a4 decreased myofibroblast and macrophage content at the site of injury, with both cell populations being key drivers of fibrotic progression. Finally, S100a4-lineage cells were shown to convert into α-SMA^+^ myofibroblasts. On the other hand, one of the major concerns that the reviewers had was your conclusion that these changes were all due to cell non- autonomous actions. This needs to be addressed more completely since S100a4 is expressed in the tendon. Moreover, the issue of how the macrophages are contributing to the phenotype should be explored. Other important comments are noted below but these two issues require detailed characterization.

Reviewer \#1:

In the present study the authors showed that S100a4 drives fibrotic tendon healing through a cell non-autonomous process; S100a4 haploinsufficiency promoted regenerative tendon healing and inhibition of S100a4 via antagonism of its putative receptor, RAGE, decreased scar formation. Also knock-down of S100a4 decreased myofibroblast and macrophage content at the site of injury, with both cell populations being key drivers of fibrotic progression. Finally, S100a4-lineage cells were shown to convert into α-SMA^+^ myofibroblasts.

Overall, the manuscript provides some new insight into the role of early, S100a4 progenitors in promoting fibrous healing, a major clinical problem. In essence, the authors have shown the cell non-autonomous actions via the global knockout on tendon healing, but we are left not understanding the relative contribution of the cell autonomous actions, nor is the mechanism of this multifunctional protein during injury clearly elucidated. The lineage tracing supporting a transition from S100a4 to α-SMA are consistent and are important results. But several questions arise from the data presented:

1\) Were there any sex differences in the haploinsufficiency mice relative the injury phenotype? to circulating levels of S100a4.

2\) Can the authors provide a quantitation of the increase in highly aligned, mature collagen fibers in the haploinsufficient model.

3\) One essential element that is missing in balancing cell autonomous vs cell non-autonomous actions. Is a macrophage specific condition deletion or a tenocyte conditional mouse available? Have the authors considered how else to distinguish tenocyte vs macrophage derived S100a4 effects on tendon healing?

4\) Does S100a4 bind only to the RAGE receptor or are there other receptors? Is RAP specific for the RAGE receptor or does it have other ligands? Is the RAGE null mouse available and would that mouse show enhanced healing after injury?

5\) The S100a4-TK experiment demonstrated a marked reduction in strength post injury? This would imply a dose dependent difference in the impact on healing of S100a4 and complicates the interpretation. Thus, there must be a complex role for S100a4 in tendon healing. Are there any in vitro data to support the kind of relationship that is U-shaped? Is it conceivable that the temporal deletion using the TK mouse might have other cell non-autonomous effects from GCV- TK? Is the timing of the temporal deletion critical for the S100a4 effects?

Reviewer \#2:

In this manuscript Ackerman et al. show that S100a4 haploinsufficiency improves tendon healing and antagonism of its putative receptor decreases scar formation. The ability to show improved tendon healing properties in a partial loss of function model are very exciting findings. The authors present possible mechanisms for how S100a4 may be acting during healing, including regulating macrophage phenotypes, matrix gene expression, and formation of SMA^+^ myofibroblasts. I think the paper would be of interest to the broad readership at *eLife*, but there are some issues that should first be addressed.

The main concern is in regards to the authors\' conclusion that they have demonstrated that S100a4 promotes scar-mediated healing via \'cell non-autonomous mechanisms\'. It would help if the authors could better explain how their data supports this conclusion. The authors show that S100a4-active and lineage cells are found throughout the tendon before and during healing. It also appears that the cells that are expressing S100a4 are co-expressing RAGE (Figure 5A). In addition, the use of haploinsufficient S100a4 or RAP injection to disrupt S100a4 gene/pathway function does so throughout all tissues in the animal, making it difficult to interpret cell autonomous or cell non-autonomous mechanisms. Cell or temporal specific loss of function studies and demonstrating that S100a4 is signaling through RAGE seem necessary to make such conclusions.

Is there a difference in tendon properties in the S100a4 hets compared to wild types prior to injury? It appears that many cells in the tendon are S100a4^GFP+^ prior to injury, and it is unclear if S100a4 haploinsufficiency results in tendons that are different prior to injury (Figure 2D-G). As this haploinsufficient model is not tissue or temporally specific, it would help to distinguish injury-specific roles of S100a4 vs a general role in the tendon.

Please indicate the stages of healing that are shown in Figure 3. In Figure 3F, it appears that there are more vessels with strong SMA labeling in the S100a4 hets. Do the S100a4 hets have increased vasculature in the healing area?

There are a few figures where cells are described as \'decreased\', \'few\' or \'most\' (subsection "S100a4 modulates macrophage function", Discussion section). It would help if there was some sort of quantification of this data. Specifically- the reduction in macrophages for Figure 4A and a quantification of the SMA co-expressing cells populations.

The authors show exogenous addition of S100a4 is sufficient to alter macrophage gene expression, but their model of improved tendon healing is with S100a4 haploinsufficiency. Does S100a4 haploinsufficiency alter macrophage phenotypes? Previous studies (Dulyaniova et al., 2018 and Li et al., 2010) showing S100a4 is necessary for macrophage chemotaxis use S100a4^-/-^ null mutants. It would better support their model if they showed that S100a4 het macrophages have abnormal migration or polarization.

There appear to be increased S100a4 cells near the sutures in Figure 6C. Shouldn\'t these cells be depleted or reduced in the S100a4-TK model?

The authors conclude that RAP-mediated inhibition of S100a4-RAGE activity is insufficient to improve mechanical properties (in contrast with S100a4 hets) and that S100a4 may act independently of RAGE (Discussion section). It is also possible that a constitutive haploinsufficiency (loss throughout development and adulthood in all tissues) may not recapitulate an acute pathway loss during adult healing. The possibility that S100a4 haploinsufficiency causes earlier defects or changes in other tissues that could indirectly cause this phenotype should also be considered as there are differences in these loss of function models.

Reviewer \#3:

The authors present an excellent study examining the role of S1004a in tendon healing. They use multiple mouse models, including reporters, cell ablation, and haploinsufficiency to demonstrate S1004a involvement in tendon healing. Furthermore, using genetic and pharmacological approaches, they show the therapeutic potential for targeting S1004a in tendon healing.

1\) The authors should expand their Discussion section on the limitations of the flexor tendon injury and repair model. This model does not approximate human flexor tendon injury and repair, as rehabilitation cannot be implemented. They should also modify their Introduction, to describe tendon healing in general, and remove the specific reference to flexor tendon repairs. Nonetheless, their approach is a good basic science model model for studying tendon healing.

2\) The authors are commended for measuring gliding function and tensile properties. However, they do not include normalized (material) properties such as failure stress, modulus, and toughness/energy. These properties require the measurement of cross sectional area, which would also serve as a valuable measure of scar formation.

3\) Data should be presented as mean +/- standard deviation, which I believe is a more valuable measure of the variability in the measures.

4\) Figure 1D shows that, at D3, S100a4 is not expressed in tendon, but it is expressed again by D7. Is this an artifact of the imaging, or does the expression pattern in the tendon really shift dramatically over the course of a few days?

5\) The authors should add quantification of the patterns shown in B and D, so that the percentage of S100a4-lineage vs. S100a4-active cells can be determined in the tendon and scar.

6\) The results for S100a4^GFP/+^ are impressive. The authors validated a \~50% decrease in s100a4 at the gene and protein levels. They found increased range of motion and increase failure load. Typically, tendon treatment approaches that suppress fibrosis lead to increased motion but also to decreased strength. These results imply regeneration, not just decreased ECM production. However, the authors did not report material properties; decreased scar and increased failure load implies even better improvements in failure stress and modulus. Furthermore, 14d of healing is a relatively short time frame for collagen production and remodeling, and a longer healing timepoint would be valuable. These points should be discussed by the authors.

7\) In Figure 4, the authors should add sections stained for M1 vs. M2 phenotype. They can also look for M1 vs. M2 markers using qPCR. These assessments from in vivo samples would reinforce the relevance of the very strong in vitro studies.

8\) The RAGE antagonist experiments in Figure 5 nicely show the therapeutic potential of targeting S100a4.

9\) The results in Figure 6 and Figure 7 are more typical of attempts to shut down fibrosis: improved range of motion but decreased strength. A puzzling result is that complete ablation throughout the healing period (Figure 7) led to decreased ROM and decreased strength. This isn\'t logical and should be discussed by the authors.

10\) The schematic in Figure 8 is speculative. The authors should perform the experiments with an inducible Cre and in using tendon-specific targeting to more accurately trace the source and lineage of the cells. Alternatively, in situ hybridization can be performed to track expression patterns over time.

11\) The authors should discuss the limitations that their mouse models are neither tendon specific nor inducible.

10.7554/eLife.45342.023

Author response

> Summary:
>
> All three reviewers were positively inclined and felt the data are novel and potentially important. You have shown that S100a4 drives fibrotic tendon healing, possibly through a cell non-autonomous process; S100a4 haploinsufficiency promoted regenerative tendon healing and inhibition of S100a4 via antagonism of its putative receptor, RAGE, decreased scar formation. Also knock-down of S100a4 decreased myofibroblast and macrophage content at the site of injury, with both cell populations being key drivers of fibrotic progression. Finally, S100a4-lineage cells were shown to convert into α-SMA^+^ myofibroblasts. On the other hand, one of the major concerns that the reviewers had was your conclusion that these changes were all due to cell non- autonomous actions. This needs to be addressed more completely since S100a4 is expressed in the tendon. Moreover, the issue of how the macrophages are contributing to the phenotype should be explored. Other important comments are noted below but these two issues require detailed characterization.
>
> Reviewer \#1:
>
> In the present study the authors showed that S100a4 drives fibrotic tendon healing through a cell non-autonomous process; S100a4 haploinsufficiency promoted regenerative tendon healing and inhibition of S100a4 via antagonism of its putative receptor, RAGE, decreased scar formation. Also knock-down of S100a4 decreased myofibroblast and macrophage content at the site of injury, with both cell populations being key drivers of fibrotic progression. Finally, S100a4-lineage cells were shown to convert into α-SMA^+^ myofibroblasts.
>
> Overall, the manuscript provides some new insight into the role of early, S100a4 progenitors in promoting fibrous healing, a major clinical problem. In essence, the authors have shown the cell non-autonomous actions via the global knockout on tendon healing, but we are left not understanding the relative contribution of the cell autonomous actions, nor is the mechanism of this multifunctional protein during injury clearly elucidated. The lineage tracing supporting a transition from S100a4 to α-SMA are consistent and are important results. But several questions arise from the data presented:
>
> 1\) Were there any sex differences in the haploinsufficiency mice relative the injury phenotype? to circulating levels of S100a4.

The healing phenotype trends observed when male and female data are analyzed together were consistent when each sex was analyzed separately. For example, gliding resistance was significantly reduced in male and female S100a4^GFP/+^ repairs, relative to sex-matched WT repairs. MTP flexion angle and max load were increased in male and female S100a4-^GFP/+^ repairs, relative to sex-matched WT repairs. These differences were not statistically significant, likely due to the limited power of the smaller data sets. While there is no clear evidence of sexual dimorphism with respect to S100a4 levels or expression in the literature, S100a4^-/-^ mice are born with an abnormal sex distribution (fewer females). In addition, Erlandsson et al., demonstrated that female S100a4^-/-^ mice were resistant to ovariectomy-induced bone loss, relative to WT (Erlandsson et al., 2013). Moreover, Dempsie et al., demonstrate that overexpression of S100a4 in females leads to increased pulmonary artery hypertension (PAH) lesions, while S100a4 overexpression in males does not have an effect and they suggest that the higher incidence of pulmonary artery hypertension that is observed in females is due to elevated levels of S100a4 (Dempsie et al., 2011).

> 2\) Can the authors provide a quantitation of the increase in highly aligned, mature collagen fibers in the haploinsufficient model.

We attempted to use Second Harmonic Generation multiphoton imaging to analyze collagen alignment, however this approach was unsuccessful due to technical limitation, likely related to sample thickness. Since we were not able to provide quantitative data to support this conclusion, we have revised the Results section as appropriate.

> 3\) One essential element that is missing in balancing cell autonomous vs cell non-autonomous actions. Is a macrophage specific condition deletion or a tenocyte conditional mouse available? Have the authors considered how else to distinguish tenocyte vs macrophage derived S100a4 effects on tendon healing?

This is a very good point, and something we are interested in addressing. We are currently generating both macrophage and tendon conditional S100a4 knockout animals, but these studies are just beginning. To begin to identify the specific cells that express S100a4 during tendon healing we have crossed S100a4-GFP^promoter+^ mice to Csf1r-CreER; Rosa-Ai9 mice, which allows us to determine whether macrophage lineage cells actively express S100a4 during healing. These data, which are presented in new Figure 4---figure supplement 1 demonstrate that many macrophages express S100a4 during early tendon healing, and support the future use of macrophage conditional S100a4 deletion. Moreover, there is also a population of S100a4^+^ cells that are not Csf1r-lineage, supporting the future use of additional Cre drivers to delineate the relative contributions of discrete populations of S100a4^+^ cells.

To address the cell autonomous vs. cell non-autonomous function of S100a4 we isolated primary bone marrow derived macrophages (BMDMs) and primary tendon cells from WT and S100a4^GFP/+^ mice. No changes in BMDM migration in vehicle treated BMDM were observed between WT and S100a4^GFP/+^ cells, and there was a consistent enhancement in migration in response to exogenous S100a4 in both genotypes (Figure 4---figure supplement 2B). Thus, suggesting that S100a4 haploinsufficiency does not alter intrinsic macrophage function and that the macrophage response to S100a4 is largely cell non-autonomous. In addition, no changes in polarization were observed between WT and S100a4^GFP/+^ BMDMs (Figure 4---figure supplement 2E and F). In primary tendon cells, no changes in expression of tenogenic or matrix related genes were observed between WT and S100a4^GFP/+^ cells (Figure 4---figure supplement 3A and B). In addition, S100a4 haploinsufficiency did not alter tendon cell proliferation (Figure 4---figure supplement 3C). However, migration, as assessed by scratch wound closure, was significantly increased in S00a4^GFP/+^ tendon cells (Figure 4---figure supplement 3D), suggesting that S100a4 has both cell autonomous and cell non-autonomous functions in tendon cells.

> 4\) Does S100a4 bind only to the RAGE receptor or are there other receptors? Is RAP specific for the RAGE receptor or does it have other ligands? Is the RAGE null mouse available and would that mouse show enhanced healing after injury?

In addition to RAGE, there is evidence that S100a4 can interact with TLR4 (Björk et al.), EGFR ligands (Klingelhofer et al., 2009), Heparan Sulfate Proteoglycans (Kiryushko et al., 2006), and cell surface Annexin 2 (Semov et al., 2005). While the role of these molecules in tendon healing is not clear, it will be important to define the RAGE independent mechanisms of S100a4 in future studies, and we have discussed this in the revised manuscript (Discussion section).

RAP is specific for blocking ligand binding to RAGE, however, RAP also prevents other RAGE ligands, such as HMGB-1 and S100P from binding. Thus, we believe that the differences in healing phenotypes observed between S100a4^GFP/+^ and RAP treated animals may be due to a combination of S100a4 signaling through receptors other than RAGE, and inhibition of RAGE signaling via ligands other than S100a4. We have included these as limitations in the Discussion section.

We have recently received RAGE^-/-^ mice and anticipate that these mice will heal in a manner similar to RAP treated animals, however, these mice will also clarify the effects of sustained RAGE inhibition, relative to the delayed inhibition that occurs with RAP.

> 5\) The S100a4-TK experiment demonstrated a marked reduction in strength post injury? This would imply a dose dependent difference in the impact on healing of S100a4 and complicates the interpretation. Thus, there must be a complex role for S100a4 in tendon healing. Are there any in vitro data to support the kind of relationship that is U-shaped? Is it conceivable that the temporal deletion using the TK mouse might have other cell non-autonomous effects from GCV- TK? Is the timing of the temporal deletion critical for the S100a4 effects?

This raises two important points regarding S100a4: i) dose-dependent effects and, ii) time-dependent effects.

In terms of timing, it is clear that the timing cell depletion alters the healing response (Figure 6 and Figure 7). However, we have not addressed the effects of inducible or delayed S100a4 haploinsufficiency. Moreover, it is likely that modifying the timing of RAP treatment to inhibit S100a4-RAGE signaling would alter the healing response, and based on the effects of S100a4^+^ cell depletion during the acute inflammatory phase of healing (S100a4-TK\[D1-14\]; Figure 7), we would hypothesize that RAP treatment at this time would also be detrimental. Future studies using an inducible Cre driver and S100a4^flox^ mice will provide important clarity on the time-dependent functions of S100a4 during healing, which we have addressed in the Discussion section.

In terms of a dose-dependent effect on healing, this is more complicated to address particularly in the S100a4-TK mice, since as the reviewer notes there are likely to be non-autonomous effects on other cells due to the increase in apoptotic cells in the healing environment. With respect to in vitro data, the data in Figure 4---figure supplement 2A modestly suggest a potential U-shaped response to exogenous S100a4, as significant increases in migration are observed in WT bone marrow derived macrophages in response to 50, 200, and 100ng/mL recombinant S100a4, while no increases are observed with 500ng/mL treatment. However, these data are not sufficient to clearly demonstrate dose-dependent effects of S100a4.

> Reviewer \#2:
>
> In this manuscript Ackerman et al. show that S100a4 haploinsufficiency improves tendon healing and antagonism of its putative receptor decreases scar formation. The ability to show improved tendon healing properties in a partial loss of function model are very exciting findings. The authors present possible mechanisms for how S100a4 may be acting during healing, including regulating macrophage phenotypes, matrix gene expression, and formation of SMA^+^ myofibroblasts. I think the paper would be of interest to the broad readership at eLife, but there are some issues that should first be addressed.
>
> The main concern is in regards to the authors\' conclusion that they have demonstrated that S100a4 promotes scar-mediated healing via \'cell non-autonomous mechanisms\'. It would help if the authors could better explain how their data supports this conclusion. The authors show that S100a4-active and lineage cells are found throughout the tendon before and during healing. It also appears that the cells that are expressing S100a4 are co-expressing RAGE (Figure 5A). In addition, the use of haploinsufficient S100a4 or RAP injection to disrupt S100a4 gene/pathway function does so throughout all tissues in the animal, making it difficult to interpret cell autonomous or cell non-autonomous mechanisms. Cell or temporal specific loss of function studies and demonstrating that S100a4 is signaling through RAGE seem necessary to make such conclusions.
>
> Is there a difference in tendon properties in the S100a4 hets compared to wild types prior to injury? It appears that many cells in the tendon are S100a4^GFP+^ prior to injury, and it is unclear if S100a4 haploinsufficiency results in tendons that are different prior to injury (Figure 2D-G). As this haploinsufficient model is not tissue or temporally specific, it would help to distinguish injury-specific roles of S100a4 vs a general role in the tendon.

This is very good point. To address this, we evaluated the gliding and biomechanical properties of uninjured contralateral FDL tendons. No significant differences in MTP Flexion Angle, Gliding Resistance, max load at failure, or stiffness were observed between genotypes. This data is presented in Figure 2---figure supplement 1.

> Please indicate the stages of healing that are shown in Figure 3. In Figure 3F, it appears that there are more vessels with strong SMA labeling in the S100a4 hets. Do the S100a4 hets have increased vasculature in the healing area?

The data in Figure 3 were collected at 14 days post-surgery, which corresponds to the proliferative phase of healing. We have updated both the text and figure legend to include this information.

In terms of increased vasculature in S100a4^GFP/+^ repairs, we examined n=4-5 specimens per genotype and observed a relatively consistent level of vascularity in the healing area between WT and S100a4^GFP/+^ repairs. We agree that there is more pronounced α-SMA staining in the vessels of S10a04^GFP/+^ repairs in Figure 3F, though this may also be due to the plane of section through the vessels. Interestingly, there is evidence of synergistic effects for S100a4 and VEGF (via RAGE signaling) to promote endothelial cell migration and enhanced vascularity (Grum-Schwensen et al., 2005; Hernandez et al., 2013; Ochiya, Takenaga and Endo, 2014), which would actually suggest the hypothesis of decreased vasculature in S100a4^GFP/+^ repairs.

> There are a few figures where cells are described as \'decreased\', \'few\' or \'most\' (subsection "S100a4 modulates macrophage function", Discussion section). It would help if there was some sort of quantification of this data. Specifically- the reduction in macrophages for Figure 4A and a quantification of the SMA co-expressing cells populations.

We have now included quantification of the S100a4^Lin+^ population and S100a4-GFP^promoter+^ population over time (new Figure 1C and F), F4/80, iNOS and IL1ra expression in WT and S100a4^GFP/+^ repairs (new Figure 4A-D), and the S100a4^Lin+^; α-SMA^+^ and S100a4-GFP^promoter+^; α-SMA^+^ populations (new Figure 8C). We have also revised the Results section and Discussion section to reflect the conclusions that can be drawn from this quantitative data and have updated the Materials and methods section.

> The authors show exogenous addition of S100a4 is sufficient to alter macrophage gene expression, but their model of improved tendon healing is with S100a4 haploinsufficiency. Does S100a4 haploinsufficiency alter macrophage phenotypes? Previous studies (Dulyaniova et al., 2018 and Li et al., 2010) showing S100a4 is necessary for macrophage chemotaxis use S100a4^-/-^ null mutants. It would better support their model if they showed that S100a4 het macrophages have abnormal migration or polarization.

This is a very good point. To address this, we isolated primary bone marrow derived macrophages (BMDM) from S100a4^GFP/+^ and WT mice. These data demonstrate that S100a4 haploinsufficiency does not alter macrophage migration, nor does it impair the pro-migratory effects of exogenous S100a4 on macrophages (Figure 4---figure supplement 2B). These data are in contrast to the migration phenotype observed with complete deletion of S100a4, suggesting that there may be an S100a4 expression threshold below which defects in migration occur. In addition, it is unknown how S100a4^-/-^ macrophages respond to exogenous S100a4 treatment, which would further clarify the roles of cell autonomous vs. non-autonomous S100a4 in macrophages. These data are now further discussed in the Discussion. In addition, no changes in polarization were observed between WT and S100a4^GFP/+^ BMDMs at baseline, or in response to exogenous S100a4 (Figure 4---figure supplement 2E and F).

> There appear to be increased S100a4 cells near the sutures in Figure 6C. Shouldn\'t these cells be depleted or reduced in the S100a4-TK model?

We examined n=4 samples of S100a4-TK (D5-10) mice at D14 and consistently observed a persistent S100a4+ population for which the image in Figure 6C is representative. Lack of depletion of these cells is either due to incomplete depletion of proliferating S100a4-TK cells with the GCV regimen (GCV has a very short half-life so is administered every 12hrs, however even this regimen is not likely to achieve 100% depletion), or because these cells were not actively proliferating and/or expressing S100a4 during GCV treatment. That is, since GCV treatment was ended at D10 and the histology and gliding/ mechanics samples were harvested at D14 there is likely a population of non-depleted cells that express S100a4 between D10-14. We have revised the Results section, Materials and methods section and figure legends to clarify the timing of histological analysis of S100a4-TK (D5-10) mice.

> The authors conclude that RAP-mediated inhibition of S100a4-RAGE activity is insufficient to improve mechanical properties (in contrast with S100a4 hets) and that S100a4 may act independently of RAGE (Discussion section). It is also possible that a constitutive haploinsufficiency (loss throughout development and adulthood in all tissues) may not recapitulate an acute pathway loss during adult healing. The possibility that S100a4 haploinsufficiency causes earlier defects or changes in other tissues that could indirectly cause this phenotype should also be considered as there are differences in these loss of function models.

This is a good point. As noted above, we now provide data that S100a4 haploinsufficiency does not significantly alter gliding function or mechanical properties of un-injured adult flexor tendons (Figure 2---figure supplement 1), suggesting that S100a4 haploinsufficiency, and therefore diminished S100a4-RAGE signaling does not disrupt tendon homeostasis. However, in addition to acknowledging that S100a4 may act independently of RAGE, we now also include text to reflect the possibility that S100a4 haploinsufficiency in other cells or tissues may impact the tendon healing phenotype in S100a4^GFP/+^ repairs (Discussion section).

> Reviewer \#3:
>
> The authors present an excellent study examining the role of S1004a in tendon healing. They use multiple mouse models, including reporters, cell ablation, and haploinsufficiency to demonstrate S1004a involvement in tendon healing. Furthermore, using genetic and pharmacological approaches, they show the therapeutic potential for targeting S1004a in tendon healing.
>
> 1\) The authors should expand their Discussion section on the limitations of the flexor tendon injury and repair model. This model does not approximate human flexor tendon injury and repair, as rehabilitation cannot be implemented. They should also modify their Introduction, to describe tendon healing in general, and remove the specific reference to flexor tendon repairs. Nonetheless, their approach is a good basic science model model for studying tendon healing.

We have acknowledged the limitations of this model of healing in revised manuscript (Discussion section), including the importance of physical therapy to improving the healing process. We have also revised the introduction to reflect the general process of tendon healing and have added references to support the complications of healing in other tendons rather than focusing only on the flexor tendon (Introduction).

> 2\) The authors are commended for measuring gliding function and tensile properties. However, they do not include normalized (material) properties such as failure stress, modulus, and toughness/energy. These properties require the measurement of cross sectional area, which would also serve as a valuable measure of scar formation.

Thank you for this comment, it is an important point. Given that the measures of gliding function and tensile properties are conducted with the tendon in situ to maintain and account for scar tissue adhesions between the tendon and surrounding tissues, it has not been possible to measure cross-sectional area and therefore to calculate material properties. However, we are currently developing a non-invasive ultrasound approach that will facilitate measurement of cross-sectional area and subsequent calculation of material properties in future studies.

> 3\) Data should be presented as mean +/- standard deviation, which I believe is a more valuable measure of the variability in the measures.

Quantitative data are now presented +/- Standard deviation.

> 4\) Figure 1D shows that, at D3, S100a4 is not expressed in tendon, but it is expressed again by D7. Is this an artifact of the imaging, or does the expression pattern in the tendon really shift dramatically over the course of a few days?

There are a small number of S100a4^+^ cells in the tendon stubs at D3, however this low cellularity is consistent both between S100a4-GFP^promoter^ samples from this experiment and general histological assessment of D3 in this model. This finding is consistent with a transient decrease in the cellularity of the tendon ends during early healing, as Wu et al., have shown that apoptosis of tenocytes peaks at D3 following injury (Wu et al., 2010), followed by migration of tenocytes from tendon tissue away from the repair to the tendon ends (Sharma and Maffulli, 2006), as well as the likely influx of extrinsic cells.

> 5\) The authors should add quantification of the patterns shown in B and D, so that the percentage of S100a4-lineage vs. S100a4-active cells can be determined in the tendon and scar.

We have now provided quantification of these data, which are presented in new Figure 1C and F. Interestingly, quantification of S100a4GFP^promoter+^ cells demonstrates peak percent S100a4^+^ area at D14 post-surgery. Given that we quantified% (+) area it is not possible to directly compare Lin^+^ vs. Promoter^+^ cells, however, we are currently generating S100a4^Lin+^; S100a4-GFP^promoter+^ mice to understand the relationship between these populations in future work.

> 6\) The results for S100a4^GFP/+^ are impressive. The authors validated a \~50% decrease in s100a4 at the gene and protein levels. They found increased range of motion and increase failure load. Typically, tendon treatment approaches that suppress fibrosis lead to increased motion but also to decreased strength. These results imply regeneration, not just decreased ECM production. However, the authors did not report material properties; decreased scar and increased failure load implies even better improvements in failure stress and modulus. Furthermore, 14d of healing is a relatively short time frame for collagen production and remodeling, and a longer healing timepoint would be valuable. These points should be discussed by the authors.

This is a good point. As noted above we are developing an ultrasound imaging approach to measure cross-sectional area, which will allow calculation of material properties in future studies. We have included lack of material property characterization as a limitation of this study (Discussion section). In addition, we have also discussed the limitation of assessing healing only at 14 days post-surgery (Discussion section).

> 7\) In Figure 4, the authors should add sections stained for M1 vs. M2 phenotype. They can also look for M1 vs. M2 markers using qPCR. These assessments from in vivo samples would reinforce the relevance of the very strong in vitro studies.

We have now included staining for M1 (iNOS) and M2 (IL1ra) macrophage markers (new Figure 4B and C), which demonstrates a reduction in M1 macrophages, and no effect on M2 macrophages in S100a4^GFP/+^ repairs relative to WT, supporting a less inflammatory environment in S100a4^GFP/+^ repairs.

> 8\) The RAGE antagonist experiments in Figure 5 nicely show the therapeutic potential of targeting S100a4.

Thank you.

> 9\) The results in Figure 6 and Figure 7 are more typical of attempts to shut down fibrosis: improved range of motion but decreased strength. A puzzling result is that complete ablation throughout the healing period (Figure 7) led to decreased ROM and decreased strength. This isn\'t logical and should be discussed by the authors.

We agree that the well-characterized response to disrupting the fibrotic process, typically via inhibition of the acute inflammatory phase, is improved ROM and decreased mechanics. While it is not entirely clear why depletion of S100a4-TK^+^ cells from D1-14 does not improve ROM (Figure 7), these data may suggest that it is actually the depletion of the cells themselves that is driving this unexpected decrease in ROM, rather than the decrease in S100a4 expression. As we begin to identify the different cell populations that express S100a4 during tendon healing, we will not only be able to define the discrete roles of S100a4 production from these cells, but it will also help clarify why sustained depletion of S100a4^+^ cells decreases ROM, and which cell populations are particularly involved in scar formation and remodeling.

> 10\) The schematic in Figure 8 is speculative. The authors should perform the experiments with an inducible Cre and in using tendon-specific targeting to more accurately trace the source and lineage of the cells. Alternatively, in situ hybridization can be performed to track expression patterns over time.

We have revised the schematic to reflect the diversity of S100a4^+^ cells, including macrophages and tendon cells, and acknowledge in both the figure legend and the text that there are multiple S100a4-expressing cell types, including those yet to be identified. We also clarify that this a proposed mechanism of S100a4 during pro-fibrotic tendon healing, rather than conclusions drawn from the data. We agree that S100a4 conditional deletion in tendon cells will be important, and we plan to conduct these studies, unfortunately that work cannot be completed in a reasonable timeframe and are outside the scope of the present study. We have discussed these limitations in the revised manuscript (Discussion section).

> 11\) The authors should discuss the limitations that their mouse models are neither tendon specific nor inducible.

We have included a discussion of these limitations within the text of the manuscript (Discussion section).
